Physician profile
Jeffrey A George
NPI 1902878481
$3,485.27
in general payments reported to CMS, 2019-2025
32 companies · $19.43 in 2025
The $19.43 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $927 · 2021: $1,273 · 2022: $572 · 2023: $116 · 2025: $19.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $135.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $386.06 | 2019-2023 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $380.16 | 2019-2022 | |
| Abbvie INC. | $320.33 | 2021-2023 | |
| Novo Nordisk INC | $231.76 | 2019-2022 | |
| Amgen INC. | $223.51 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $191.28 | 2019-2021 | |
| Allergan, INC. | $185.70 | 2019-2020 | |
| Alfasigma USA, INC. | $168.90 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.25 | 2019-2022 | |
| Lilly USA, LLC | $157.50 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $150.24 | 2019-2022 | |
| Abbott Laboratories | $124.44 | 2021-2025 | Proclaim |
| Esperion Therapeutics, INC. | $116.19 | 2020-2021 | |
| Ambu INC. | $91.46 | 2021 | |
| Jazz Pharmaceuticals INC. | $68.35 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $64.43 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $58.32 | 2019-2022 | |
| Genentech USA, INC. | $56.94 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $40.76 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.85 | 2022 | |
| Eisai INC. | $33.12 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $31.32 | 2021 | |
| Sanofi Pasteur INC. | $31.30 | 2019-2020 | |
| Adlon Therapeutics L.P. | $31.17 | 2020 | |
| Clarus Therapeutics INC. | $24.90 | 2021 | |
| Alkermes, INC. | $21.44 | 2020 | |
| Avion Pharmaceuticals | $20.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.58 | 2019 | |
| Dermira, INC. | $17.84 | 2020 | |
| Almatica Pharma LLC | $15.97 | 2022 | |
| Braintree Laboratories, INC. | $13.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.